Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Roman Skowronski"'
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2278-2287 (2021)
Abstract American Academy of Sleep Medicine practice parameters designate sodium oxybate (SXB) as a standard of care for cataplexy, excessive daytime sleepiness (EDS), and disrupted night‐time sleep in narcolepsy. Recently, a lower‐sodium oxybate
Externí odkaz:
https://doaj.org/article/59ff0e857edc4273b36d35215aba5764
Publikováno v:
CNS Drugs. 37:323-335
Autor:
Yves Dauvilliers, Karel Šonka, Richard K. Bogan, Markku Partinen, Rafael Del Rio Villegas, Nancy Foldvary-Schaefer, Roman Skowronski, Abby Chen, Jed Black, Franck Skobieranda, Michael J. Thorpy
Publikováno v:
CNS Drugs. 36:633-647
Lower-sodium oxybate (LXB) is an oxybate medication with the same active moiety as sodium oxybate (SXB) and a unique composition of cations, resulting in 92% less sodium. LXB was shown to improve cataplexy and excessive daytime sleepiness in people w
Publikováno v:
Monday, April 24.
Autor:
Jed Black, Judi Profant, Katie Zomorodi, Roman Skowronski, Teresa L. Steininger, Gunjan Junnarkar, Clark Allphin, Cuiping Chen
Publikováno v:
Expert opinion on drug discovery. 17(2)
Introduction Sodium oxybate (SXB) is a standard of care for cataplexy, excessive daytime sleepiness, and disrupted nighttime sleep in narcolepsy. At recommended dosages in adults (6-9 g/night), SXB increases daily dietary intake of sodium by 1100-164
Autor:
Yves Dauvilliers, Karel Šonka, Richard K. Bogan, Markku Partinen, Rafael Del Rio Villegas, Nancy Foldvary-Schaefer, Roman Skowronski, Abby Chen, Jed Black, Franck Skobieranda, Michael J. Thorpy
Publikováno v:
CNS Drugs. 36:785-786
Autor:
Richard K Bogan, Michael J Thorpy, Yves Dauvilliers, Markku Partinen, Rafael Del Rio Villegas, Nancy Foldvary-Schaefer, Roman Skowronski, Lihua Tang, Franck Skobieranda, Karel Šonka
Publikováno v:
Sleep
Evaluate efficacy and safety of lower-sodium oxybate (LXB), a novel oxybate medication with 92% less sodium than sodium oxybate (SXB).Adults aged 18-70 years with narcolepsy with cataplexy were eligible. The study included a ≤30-day screening perio
Autor:
Nancy Foldvary-Schaefer, Roman Skowronski, Luke Hickey, Abby Chen, Thomas Measey, Yves Dauvilliers
Publikováno v:
Sleep. 45:A176-A176
Introduction Treatment with sodium oxybate (SXB) has been associated with weight loss in patients with narcolepsy. Lower-sodium oxybate (LXB) contains the same active moiety as SXB, with 92% less sodium, and is approved in the US for treatment of cat
Publikováno v:
Sleep. 45:A173-A173
Introduction Treatment-emergent adverse events (TEAEs) were analyzed during a 6-month open-label extension (OLE) of a double-blind, placebo-controlled, randomized withdrawal trial (NCT03030599) of lower-sodium oxybate (LXB; Xywav™). LXB is FDA appr
Publikováno v:
Sleep. 45:A177-A177
Introduction Lower-sodium oxybate (LXB) contains 92% less sodium than sodium oxybate (SXB) and is approved for treating cataplexy or excessive daytime sleepiness in patients with narcolepsy (≥7 years of age) and for treating idiopathic hypersomnia